{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:31:33Z","timestamp":1785148293949,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"DOI":"10.7759\/cureus.84911","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:40:03Z","timestamp":1748371203000},"source":"Crossref","is-referenced-by-count":2,"title":["Corticosteroid-Refractory Bullous Pemphigoid Due to Immune Checkpoint Inhibitors: A Telemedicine Challenge"],"prefix":"10.7759","author":[{"given":"Tom","family":"Marco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishab","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Recio Boiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu C","year":"2018","unstructured":"Xu C, Chen YP, Du XJ, et al.. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018, 363:k4226. 10.1136\/bmj.k4226","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5301\/tj.5000625","article-title":"Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity","volume":"103","author":"Inno A","year":"2017","unstructured":"Inno A, Metro G, Bironzo P, et al.. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori. 2017, 103:405-21. 10.5301\/tj.5000625","journal-title":"Tumori"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.015","article-title":"Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials","volume":"154","author":"Massari F","year":"2021","unstructured":"Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A, Santoni M. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021, 154:120-7. 10.1016\/j.ejca.2021.06.015","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta B","year":"2017","unstructured":"El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017, 119:1-12. 10.1016\/j.critrevonc.2017.09.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler AN","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al.. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020, 83:1255-68. 10.1016\/j.jaad.2020.03.132","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi AR","year":"2020","unstructured":"Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol. 2020, 10:91. 10.3389\/fonc.2020.00091","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.02.025","article-title":"Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma","volume":"80","author":"Correa AF","year":"2021","unstructured":"Correa AF, Jegede OA, Haas NB, et al.. Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur Urol. 2021, 80:20-31. 10.1016\/j.eururo.2021.02.025","journal-title":"Eur Urol"},{"key":"ref8","unstructured":"National Comprehensive Cancer Network. NCCN guidelines. (2025). https.\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1440."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture ME","year":"2008","unstructured":"Lacouture ME, Wu S, Robert C, et al.. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008, 13:1001-11. 10.1634\/theoncologist.2008-0131","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier J","year":"2008","unstructured":"Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008, 144:886-92. 10.1001\/archderm.144.7.886","journal-title":"Arch Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1101a155","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: a literature review","volume":"11","author":"Apalla Z","year":"2021","unstructured":"Apalla Z, Papageorgiou C, Lallas A, Delli F, Fotiadou C, Kemanetzi C, Lazaridou E. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept. 2021, 11:e2021155. 10.5826\/dpc.1101a155","journal-title":"Dermatol Pract Concept"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072084","article-title":"Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma","volume":"15","author":"Nikolaou V","year":"2023","unstructured":"Nikolaou V, Tsimpidakis A, Stratigos A. Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma. Cancers (Basel). 2023, 15:2084. 10.3390\/cancers15072084","journal-title":"Cancers (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel J","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W, et al.. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018, 79:1081-8. 10.1016\/j.jaad.2018.07.008","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer N","year":"2019","unstructured":"Kremer N, Snast I, Cohen ES, et al.. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019, 20:209-16. 10.1007\/s40257-018-0401-6","journal-title":"Am J Clin Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100289","article-title":"No oncology patient left behind: challenges and solutions in rural radiation oncology","volume":"13","author":"Kenamond MC","year":"2022","unstructured":"Kenamond MC, Mourad WF, Randall ME, Kaushal A. No oncology patient left behind: challenges and solutions in rural radiation oncology. Lancet Reg Health Am. 2022, 13:100289. 10.1016\/j.lana.2022.100289","journal-title":"Lancet Reg Health Am"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341070-corticosteroid-refractory-bullous-pemphigoid-due-to-immune-checkpoint-inhibitors-a-telemedicine-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:40:05Z","timestamp":1748371205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341070-corticosteroid-refractory-bullous-pemphigoid-due-to-immune-checkpoint-inhibitors-a-telemedicine-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.84911","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}